NOT FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, HONG KONG, SWITZERLAND, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES BESIDES THOSE REQUIRED BY SWEDISH LAW. ADDITIONAL RESTRICTIONS APPLY. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.

Ambea's rights issue oversubscribed

The preliminary result of the rights issue in Ambea AB (publ) ("Ambea" or "the Company"), for which the subscription period ended on June 5 2019, shows that the rights issue is oversubscribed. As a result of the rights issue, Ambea will receive proceeds amounting to approximately SEK 1,215 million before costs related to the rights issue.

The preliminary result shows that 26,976,854 shares, corresponding to approximately 99.9 percent of the offered shares, have been subscribed for by the exercise of subscription rights. Additionally, applications for subscription without subscription rights of 31,914,537 shares, corresponding to approximately 118.2 percent of the offered shares, have been received. Thus, the rights issue is oversubscribed.

As a result of the rights issue, Ambea will receive proceeds amounting to approximately SEK 1,215 million before costs related to the rights issue. Through the rights issue Ambea's share capital will increase by SEK 674,173.13, from SEK 1,688,253.10 to SEK 2,362,426.23 and the total number of shares will increase by 27,001,440. After the rights issue, the number of shares in Ambea will amount to 94,617,996.

Those who have subscribed for shares without subscription rights will be allotted shares according to the principles outlined in the prospectus. As confirmation of allocation of shares subscribed for without subscription rights, a transaction note will be sent on or about 12 June 2019. Subscribed and allotted shares must be paid for in cash in accordance with the instructions in the transaction note. Nominee-registered shareholders will receive notice of allotment in accordance with the procedures of the nominee. Only those who have been allotted shares will be notified.

The final result is expected to be published on 12 June 2019. The final day for trading in paid subscribed shares (BTAs) will be 18 June 2019. The new shares are expected to start trading on Nasdaq Stockholm on or about 25 June 2019.

Advisors

In connection with the rights issue, Ambea has appointed Danske Bank and DNB Markets as financial advisors, Joint Global Coordinators and Joint Bookrunners, Nordea as financial advisor and Joint Bookrunner as well as Vinge as legal advisor.

For more information, contact:

Jacob Persson, Head of Investor Relations
Telephone: +46 (0)708 64 07 52
E-mail: jacob.persson@ambea.se

Ambea press contact
Telephone: +46 (0)10 33 00 501
E-mail: press@ambea.se

This information is information that Ambea AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on June 10, 2019 at 21:00

Ambea is the market leading care provider in Sweden, Norway and Denmark respectively, with over 900 care units and around 26,000 employees. We offer services in disabled care, individual and family care, and elderly care with a focus on residential care and own management. We aim to be the quality leader in all that we do and our vision is to make the world a better place, one person at a time. The company was founded in 1996 and its head office is located in Solna, Sweden. Ambea is listed on Nasdaq Stockholm.

Imporant information

The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares or other securities in Ambea. No action has been taken and measures will not be taken to permit a public offering in any jurisdictions other than Sweden. Any invitation to the persons concerned to subscribe for shares in Ambea will only be made through the prospectus that Ambea estimates to publish on or about 21 May 2019.

The information in this press release may not be released, published or distributed, directly or indirectly, in or into the United States (including its territories and provinces, every state in the United States and the District of Columbia, ("United States")), Canada, Australia, Japan, Hong Kong, Switzerland, New Zealand, Singapore, South Africa or any other jurisdiction in which such action would be unlawful, is subject to legal restrictions or would require other measures than those required by Swedish law. Actions in violation of these restrictions may constitute a violation of applicable securities laws.

No shares or other securities in Ambea have been registered, and no shares or other securities will be registered, under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or the securities legislation of any state or other jurisdiction in the United States and no shares or other securities may be offered, sold or otherwise transferred, directly or indirectly, in or into the United States, except under an available exemption from, or in a transaction not subject to, the registration requirements under the U.S. Securities Act and in compliance with the securities legislation in the relevant state or any other jurisdiction of the United States.

This press release may contain forward-looking statements which reflect Ambeas's current view on future events and financial and operational development. Words such as "intend", "expect", "anticipate", "may", "believe", "plan", "estimate" and other expressions which imply indications or predictions of future development or trends, and which are not based on historical facts, are intended to identify forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties as they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the actual outcome could differ materially from the forward-looking statements.